Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Market Domination host Josh Lipton and guest host, Bullseye American Ingenuity Fund Portfolio Manager Adam Johnson, focus in ...

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

The Novo Nordisk Foundation started a dialog with Novo’s board “on the merits of an accelerated CEO succession,” Novo said, ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Novo Nordisk's stock is still up more than 250% since Jørgensen ... a new CEO following the foundation's request, recent market challenges and the steep decline in the company's share price.

Despite this success, recent market challenges and a decline in ... Despite the leadership change at Novo Nordisk causing the stock price to stumble, a 10.4% increase in the company’s stock ...